Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/cam4.3754 http://scihub22266oqcxt.onion/10.1002/cam4.3754 33547886!7940220!33547886     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33547886&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Cancer+Med 2021 ; 10 (5): 1644-1655 Nephropedia Template TP {{tp|p=33547886|t=2021. Effect of antitumor therapy on cancer patients infected by SARS-CoV-2: A systematic review and meta-analysis |pdf=|usr=}}{{33547886}} gab.com Text Effect of antitumor therapy on cancer patients infected by SARS-CoV-2: A systematic review and meta-analysis JO: Cancer Med http://www.kidney.de/pget.php?&tw=1&pmid=33547886 #FOAvip BACKGROUND: Cancer patients are at a high risk of being infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and are more likely to develop severe illness and have higher mortality once infected. In the COVID-19 pandemic, it is urgent to understand the effects of antitumor therapy on the prognosis of patients with COVID-19. METHODS: A systematic literature search was conducted in PubMed, Cochrane Library, Embase, MedRxiv, and Chinese National Knowledge Infrastructure (CNKI) until 21 June 2020. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were evaluated using a random effects model to analyze the effects of antitumor therapies on COVID-19 patients. RESULTS: For cancer patients with COVID-19, the death events related to antitumor treatment were higher than those with no antitumor treatment (OR = 1.55; 95% CI 1.07-2.25; p = 0.021). Compared with patients in the survival group, the non-survival group showed no significant differences in patients who received antitumor therapy. Compared with patients in the non-severe group, the severe group was more likely to receive antitumor therapy (OR = 1.50; 95% CI 1.02-2.19; p = 0.037) and there was a significant difference. The incidence of severe events was higher in the subgroup of chemotherapy (OR = 1.73; 95% CI 1.09-2.73). CONCLUSION: The synthesized evidence suggests that cancer patients with COVID-19 who received antitumor treatment shortly before symptom onset are more likely to experience severe symptoms and have high mortality. Receiving chemotherapy is an unfavorable factor for the prognosis of cancer patients with COVID-19. Twit Text FOAVip Effect of antitumor therapy on cancer patients infected by SARS-CoV-2: A systematic review and meta-analysis ????Cancer Med http://www.kidney.de/pget.php?&tw=1&pmid=33547886 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33547886 #FOAvip English Wikipedia <ref>{{Cite pmid|33547886}}</ref> Effect of antitumor therapy on cancer patients infected by SARS-CoV-2: A systematic review and meta-analysis #MMPMID33547886 Li P; Li L; Wang S; Liu Y; Li Z; Xia S Cancer Med 2021[Mar]; 10 (5): 1644-1655 PMID33547886show ga BACKGROUND: Cancer patients are at a high risk of being infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and are more likely to develop severe illness and have higher mortality once infected. In the COVID-19 pandemic, it is urgent to understand the effects of antitumor therapy on the prognosis of patients with COVID-19. METHODS: A systematic literature search was conducted in PubMed, Cochrane Library, Embase, MedRxiv, and Chinese National Knowledge Infrastructure (CNKI) until 21 June 2020. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were evaluated using a random effects model to analyze the effects of antitumor therapies on COVID-19 patients. RESULTS: For cancer patients with COVID-19, the death events related to antitumor treatment were higher than those with no antitumor treatment (OR = 1.55; 95% CI 1.07-2.25; p = 0.021). Compared with patients in the survival group, the non-survival group showed no significant differences in patients who received antitumor therapy. Compared with patients in the non-severe group, the severe group was more likely to receive antitumor therapy (OR = 1.50; 95% CI 1.02-2.19; p = 0.037) and there was a significant difference. The incidence of severe events was higher in the subgroup of chemotherapy (OR = 1.73; 95% CI 1.09-2.73). CONCLUSION: The synthesized evidence suggests that cancer patients with COVID-19 who received antitumor treatment shortly before symptom onset are more likely to experience severe symptoms and have high mortality. Receiving chemotherapy is an unfavorable factor for the prognosis of cancer patients with COVID-19. |Aged[MESH] |COVID-19/*epidemiology/mortality[MESH] |Humans[MESH] |Middle Aged[MESH] |Neoplasms/*drug therapy/*epidemiology/mortality[MESH]Effect of antitumor therapy on cancer patients infected by SARS-CoV-2:(epmc).pdf DeepDyve Pubget Overpricing